SYN

Synthetic Biologics Inc (SYN) | Rumor.io

Synthetic Biologics

SYN

Attention (50-day avg)0%

Attention rank (50-day avg)#2,482

Bullish sentiment (50-day avg)78%

Price to earnings ratio-0.11

Market capitalization2.6M

Earnings per share-1.9

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-14.3M

Social

What share of all stock conversation is about SYN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Aug 11

Synthetic Biologics reported a GAAP EPS of -$0.31 for Q2 2022.
The company filed its 10-Q form with the SEC on August 11, 2022.
Synthetic Biologics reported its second quarter 2022 operational highlights and financial results, including a net loss.

Generated by AI

Sentiment

Of the messages about SYN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% +29.13	44.34% -46.57
Bearish	0%	0%	0% -29.13	55.66% +46.57

Jan 12

Synthetic Biologics, Inc. (SYN) is expected to run hard if it breaks $0.82.
A breakout at $0.85 in SYN could lead to a return to $1.70 by Friday.
SYN may reach $1.70 if it breaks $0.90.

Generated by AI

Topics

Of the messages about SYN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	36.13%	7.58%
Technical Analysis	0%	0%	63.87%	86.49%
Analysts	0%	0%	0%	2.96%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	2.96%

Jan 6

Synthetic Biologics, Inc. (SYN) has seen a significant stock price increase, jumping 99.96% to a new 52-week high.
Synthetic Biologics has filed a form 8-K with the SEC, indicating the company has filed financial statements and exhibits, as well as other events.
There is no other market-relevant information about SYN in the provided social media posts.

Generated by AI

Community

Of the messages about SYN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	5.19%
Newcomers	100%	100%	100%	94.81%

Regulars· Mar 17

Synthetic Biologics, Inc. (SYN) reported 2021 year-end operational highlights and financial results, with a 10% increase in stock price to $0.2749 in the last 19 minutes.
The company's CEO, Steven Shallcross, discussed Q4 2021 results on an earnings call transcript, highlighting the company's performance.
The stock's MACD Histogram turned positive on March 16, 2022, indicating a potential uptrend, while the Aroon Indicator entered a downtrend, showing conflicting signals.

Newcomers· Aug 4

The focus on $SYN is its potential for a significant price increase, with some users predicting it could move big or even hit 1.90 or 2+.
There is interest in $SYN's patent news, with one user highlighting a newly published patent application for phosphatase agents for the treatment of various neurodevelopmental disorders.
New users are looking for buy signals, with some discussing the importance of getting off sell orders and waiting for a leg up, and others considering entering the stock with the potential for a nice flip.

Generated by AI

Also Discussed

Investors talking about SYN also mention

#	Name	Attention
1	ZIOP - ZIOPHARM Oncology, Inc.	——
2	NAVB - Navidea Biopharmaceuticals, Inc.	——
3	BDSI - BioDelivery Sciences International, Inc.	——
4	AEZS - Aeterna Zentaris Inc.	——
5	AcelRx Pharmaceuticals IncACRX	0%new
6	CorMedix Inc.CRMD	0%+0
7	XOMA CorporationXOMA	0%0
8	PFIE - Profire Energy, Inc.	——
9	Catalyst Pharmaceuticals Inc.CPRX	0%new
10	NVCN - Neovasc Inc.	——